Olfactory bulb tissue transplantation inhibits P2X2/3 receptor-mediated neuropathic pain. However, the olfactory bulb has a complex cellular composition, and the mechanism underlying the action of purified transplante...Olfactory bulb tissue transplantation inhibits P2X2/3 receptor-mediated neuropathic pain. However, the olfactory bulb has a complex cellular composition, and the mechanism underlying the action of purified transplanted olfactory ensheathing cells(OECs) remains unclear. In the present study, we microencapsulated OECs in alginic acid, and transplanted free and microencapsulated OECs into the region surrounding the injured sciatic nerve in rat models of chronic constriction injury. We assessed mechanical nociception in the rat models 7 and 14 days after surgery by measuring paw withdrawal threshold, and examined P2X2/3 receptor expression in L4–5 dorsal root ganglia using immunohistochemistry. Rats that received free and microencapsulated OEC transplants showed greater withdrawal thresholds than untreated model rats, and weaker P2X2/3 receptor immunoreactivity in dorsal root ganglia. At 14 days, paw withdrawal threshold was much higher in the microencapsulated OEC-treated animals. Our results confirm that microencapsulated OEC transplantation suppresses P2X2/3 receptor expression in L4–5 dorsal root ganglia in rat models of neuropathic pain and reduces allodynia, and also suggest that transplantation of microencapsulated OECs is more effective than transplantation of free OECs for the treatment of neuropathic pain.展开更多
Background Immune rejection is the main reason of grafts failure after corneal transplantation. This study was to determine whether interlerkin-1 receptor antagonist (IL-1ra) eye drops could prolong corneal allograft...Background Immune rejection is the main reason of grafts failure after corneal transplantation. This study was to determine whether interlerkin-1 receptor antagonist (IL-1ra) eye drops could prolong corneal allografts survival in high-risk corneal orthotopic allotransplantation in rat model and to study the effect of IL-1ra on the expression of CD 1-positive cells in the grafts Methods For all experiments, the Sprague-Dawley (SD) rats' corneas were transplanted into Wistar rats' eyes High-risk transplants included those that had been sutured into Wistar recipient beds with corneal neovascularization induced by placement of three interrupted sutures in the host cornea 7 days earlier All the animals were divided, in a masked fashion, into three treatment groups and one control group Each treatment group received IL-1ra eye drops of different concentrations (1 mg/ml, 3 mg/ml, or 5 mg/ml, respectively) four times a day for 30 days The control group received 0 9% normal saline (NS) eye drops in the same way as the treatment groups All allografts were evaluated for signs of rejection from the first day after surgery Ten days later, corneal specimens were processed to examine the expression of CD 1-positive cells and histopathological changes Results The survival time of the transplants was 5 80±0 79, 5 89±1 05, 6 78±0 83, and 9 00±2 36 days respectively in the control or three treatment groups Compared with the control group, 1 mg/ml IL-1ra eye drop did not prolong the survival time of the allografts ( t =0 210, P >0 05) However, 3 mg/ml and 5 mg/ml IL-1ra eye drop did prolong the survival time of the grafts ( t ≥2.627, P <0 05), with the latter showing more obvious effect Immunohistochemical examinations showed a significant decrease in inflammatory cell and CD 1-positive cell infiltration in IL-1ra treated groups compared with the control group Conclusions IL-1ra can promote corneal allograft survival in a dose-dependant manner by reducing the infiltration of CD 1-positive cells in high-risk corneal transplantation展开更多
基金supported by the National Natural Science Foundation of China,No.81260190the Natural Science Foundation of Jiangxi Province of China,No.20132BAB205023+1 种基金a grant from the Science and Technology Research Program of Department of Education of Jiangxi Province in China,No.GJJ13159a grant from the Science and Technology Program of Department of Health of Jiangxi Province,No.20132019
文摘Olfactory bulb tissue transplantation inhibits P2X2/3 receptor-mediated neuropathic pain. However, the olfactory bulb has a complex cellular composition, and the mechanism underlying the action of purified transplanted olfactory ensheathing cells(OECs) remains unclear. In the present study, we microencapsulated OECs in alginic acid, and transplanted free and microencapsulated OECs into the region surrounding the injured sciatic nerve in rat models of chronic constriction injury. We assessed mechanical nociception in the rat models 7 and 14 days after surgery by measuring paw withdrawal threshold, and examined P2X2/3 receptor expression in L4–5 dorsal root ganglia using immunohistochemistry. Rats that received free and microencapsulated OEC transplants showed greater withdrawal thresholds than untreated model rats, and weaker P2X2/3 receptor immunoreactivity in dorsal root ganglia. At 14 days, paw withdrawal threshold was much higher in the microencapsulated OEC-treated animals. Our results confirm that microencapsulated OEC transplantation suppresses P2X2/3 receptor expression in L4–5 dorsal root ganglia in rat models of neuropathic pain and reduces allodynia, and also suggest that transplantation of microencapsulated OECs is more effective than transplantation of free OECs for the treatment of neuropathic pain.
文摘Background Immune rejection is the main reason of grafts failure after corneal transplantation. This study was to determine whether interlerkin-1 receptor antagonist (IL-1ra) eye drops could prolong corneal allografts survival in high-risk corneal orthotopic allotransplantation in rat model and to study the effect of IL-1ra on the expression of CD 1-positive cells in the grafts Methods For all experiments, the Sprague-Dawley (SD) rats' corneas were transplanted into Wistar rats' eyes High-risk transplants included those that had been sutured into Wistar recipient beds with corneal neovascularization induced by placement of three interrupted sutures in the host cornea 7 days earlier All the animals were divided, in a masked fashion, into three treatment groups and one control group Each treatment group received IL-1ra eye drops of different concentrations (1 mg/ml, 3 mg/ml, or 5 mg/ml, respectively) four times a day for 30 days The control group received 0 9% normal saline (NS) eye drops in the same way as the treatment groups All allografts were evaluated for signs of rejection from the first day after surgery Ten days later, corneal specimens were processed to examine the expression of CD 1-positive cells and histopathological changes Results The survival time of the transplants was 5 80±0 79, 5 89±1 05, 6 78±0 83, and 9 00±2 36 days respectively in the control or three treatment groups Compared with the control group, 1 mg/ml IL-1ra eye drop did not prolong the survival time of the allografts ( t =0 210, P >0 05) However, 3 mg/ml and 5 mg/ml IL-1ra eye drop did prolong the survival time of the grafts ( t ≥2.627, P <0 05), with the latter showing more obvious effect Immunohistochemical examinations showed a significant decrease in inflammatory cell and CD 1-positive cell infiltration in IL-1ra treated groups compared with the control group Conclusions IL-1ra can promote corneal allograft survival in a dose-dependant manner by reducing the infiltration of CD 1-positive cells in high-risk corneal transplantation